Intercell AG

EANS-News: Joint Committee on Vaccination and Immunization (JCVI) in the UK broadens Japanese Encephalitis immunization recommendation to include Intercell vaccine

. » First country specific recommendation in Europe » Key to foster product awareness for Intercell's vaccine to prevent Japanese Encephalitis -------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Company Information Subtitle: . » First country specific recommendation in Europe » Key to foster product awareness for Intercell's vaccine to prevent Japanese Encephalitis Vienna (Austria), March 4, 2010 (euro adhoc) - Intercell AG (VSE: ICLL) today announced that Joint Committee on Vaccination and Immunization (JCVI) in the UK has recently updated the Japanese Encephalitis chapter of Immunisation against infectious diseases ("Green Book") to recommend the use of IXIARO® for individuals aged 18 years and older to protect individuals for high risk of exposure during travel or in the course of their occupation. This decision follows the expanded recommendations of the US Advisory Committee on Immunization Practices (ACIP) in 2009. Further national specific recommendations in Europe are expected for the year 2010. "We are pleased that our joint medical management efforts with our partner Novartis are materializing now also in Europe with the first country specific recommendations. Especially for novel travel vaccines recommendations are key to foster disease and product awareness and thus increasing vaccination rates and product uptake," stated Gerd Zettlmeissl, Chief Executive Officer of Intercell. Intercell's novel Japanese Encephalitis vaccine is a purified, inactivated vaccine for active immunization of adults against the Japanese Encephalitis virus. end of announcement euro adhoc -------------------------------------------------------------------------------- ots Originaltext: Intercell AG Im Internet recherchierbar: http://www.presseportal.ch Further inquiry note: Intercell AG Lucia Malfent Global Head Corporate Communications Tel. +43 1 20620-1303 communications@intercell.com Branche: Biotechnology ISIN: AT0000612601 WKN: A0D8HW Index: ATX Prime, ATX Börsen: Wien / official market

Das könnte Sie auch interessieren: